Entrada Therapeutics (TRDA) Free Cash Flow (2020 - 2026)

Entrada Therapeutics' Free Cash Flow history runs 7 years deep, the most recent figure standing at -$41.7 million for Q1 2026.

• On a quarterly basis, Free Cash Flow fell 7.98% year-over-year to -$41.7 million in Q1 2026; TTM through Mar 2026 was -$131.6 million, a 128.08% decrease from a year earlier, with the FY2025 full-year figure at -$128.5 million, down 187.4% from the prior year.
• Free Cash Flow eased to -$41.7 million in Q1 2026 per TRDA's latest filing, from -$32.3 million in the prior quarter.
• Across five years, Free Cash Flow topped out at $194.8 million in Q1 2023 and bottomed at -$41.7 million in Q1 2026.
• The 5-year median for Free Cash Flow is -$27.3 million (2023), against an average of -$10.3 million.
• Across the five-year window, Free Cash Flow surged 1010.89% in 2023 and slumped 637.76% in 2024, its largest moves.
• Year by year, Free Cash Flow stood at -$25.2 million in 2022, then jumped by 80.21% to -$5.0 million in 2023, then slumped by 637.76% to -$36.8 million in 2024, then climbed by 12.18% to -$32.3 million in 2025, then slipped by 28.99% to -$41.7 million in 2026.
• Per Business Quant, the three latest TRDA Free Cash Flow figures stand at -$41.7 million (Q1 2026), -$32.3 million (Q4 2025), and -$28.3 million (Q3 2025).